{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:04Z","timestamp":1794414424750,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pharmthera.2026.109104","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:35:54Z","timestamp":1787700954000},"page":"109104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention"],"prefix":"10.1016","volume":"288","author":[{"given":"Martina","family":"Izzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lapucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaela Anna","family":"Vascotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Calandrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella Micol","family":"Mela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palesa Caroline","family":"Koatale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Perrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2026.109104_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fruro.2026.1719136","article-title":"High-risk biochemical recurrence in prostate cancer: Identification and early intervention strategies","volume":"6","author":"Abdelaziz","year":"2026","journal-title":"Frontiers in Urology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0010","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41391-023-00767-y","article-title":"High-risk biochemical recurrence of locally treated prostate cancer after EMBARK: an end to decades of conventional wisdom?","volume":"27","author":"Achard","year":"2024","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109104_bb0015","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0020","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1200\/JCO.2010.29.8091","article-title":"Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer","volume":"28","author":"Alibhai","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2026.04.013","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2026 update. Part I: Screening, diagnosis, and local treatment with curative intent","author":"Cornford","year":"2026","journal-title":"European Urology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0035","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0040","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1517\/14656566.2014.915313","article-title":"Targeting the androgen receptor in prostate cancer","volume":"15","author":"Culig","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109104_bb0045","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14796694.2025.2475730","article-title":"Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review","volume":"22","author":"Dato","year":"2026","journal-title":"Future Oncology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136094","article-title":"Gynecomastia in patients with prostate cancer: A systematic review","volume":"10","author":"Fagerlund","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0055","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0060","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer\u2013specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0065","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.125.271770","article-title":"Salvage radiotherapy confers an overall survival advantage in biochemical recurrence of prostate cancer: Evidence from the International PROMISE registry","author":"Guberina","year":"2026","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocrine Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109104_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109104_bb0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/cancers17020215","article-title":"Early versus delayed androgen deprivation therapy for biochemical recurrence after local curative treatment in non-metastatic hormone-sensitive prostate cancer: A systematic review of the literature","volume":"17","author":"Karim","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0085","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(26)00137-6","article-title":"Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis","volume":"407","author":"Kishan","year":"2026","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.pharmthera.2026.109104_bb0090","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1080\/14796694.2025.2577633","article-title":"Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)","volume":"21","author":"Morgans","year":"2025","journal-title":"Future Oncology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0095","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"European Urology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0100","series-title":"PDQ Cancer Information Summaries","article-title":"Prostate cancer treatment (PDQ\u00ae): Health professional version","author":"PDQ Adult Treatment Editorial Board","year":"2002"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0105","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0110","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0025-6196(11)62406-3","article-title":"PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer","volume":"76","author":"Roberts","year":"2001","journal-title":"Mayo Clinic Proceedings"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109104_bb0115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa2510310","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","volume":"394","author":"Shore","year":"2026","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109104_bb0120","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/JU.0000000000004890","article-title":"Treatment of high-risk biochemically recurrent prostate cancer with enzalutamide in combination with leuprolide: Secondary endpoints from the EMBARK Trial","volume":"215","author":"Shore","year":"2026","journal-title":"The Journal of Urology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116110","article-title":"Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age","volume":"232","author":"Shore","year":"2026","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0135","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/EDBK_351033","article-title":"Best approaches and updates for prostate cancer biochemical recurrence","volume":"42","author":"Simon","year":"2022","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2026.04.014","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2026 update: Treatment of relapsing and metastatic prostate cancer","author":"Tilki","year":"2026","journal-title":"European Urology"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0145","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2026.109104_bb0150","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"Journal of Clinical Oncology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:56:29Z","timestamp":1794412589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":30,"alternative-id":["S0163725826001312"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109104","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109104"}}